Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Healthcare Biotechnology
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

GlobeNewswire February 7, 2018

Kamada to Announce Fiscal Year 2017 Financial Results and Host Conference Call on February 7

GlobeNewswire February 2, 2018

Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

GlobeNewswire January 8, 2018

Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

GlobeNewswire January 4, 2018

Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection

GlobeNewswire November 21, 2017

Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

GlobeNewswire November 20, 2017

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017

GlobeNewswire November 13, 2017

Kamada Announces Nomination of Three New Members to its Board of Directors

GlobeNewswire November 10, 2017

Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13

GlobeNewswire November 8, 2017

Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients

GlobeNewswire November 1, 2017

10 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  October 18, 2017

Kamada Announces CFO Transition

GlobeNewswire September 18, 2017

Kamada to Present Corporate Overview at Two Investor Conferences in September

GlobeNewswire September 7, 2017

Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action

GlobeNewswire September 6, 2017

Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire August 30, 2017

18 Biggest Mid-Day Gainers For Friday

Benzinga.com  August 25, 2017

Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection

GlobeNewswire August 25, 2017

Kamada Reports Financial Results for Second Quarter and First Six Months of 2017

GlobeNewswire August 1, 2017

Kamada Announces Pricing of Public Offering of Ordinary Shares

GlobeNewswire July 28, 2017

Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017

GlobeNewswire July 27, 2017